FLT3 and acute myeloid leukemia: Specifically, patients with co-occurring favorable risk features (i.e., core-binding factor AML [n = 44, 0.8%], mutated NPM1 without FLT3-ITD [n = 163, 3.0%], or bZIP in-frame mutated CEBPA [n = 23, 0.4%]) were assigned to the ELN 2022 favorable risk group regardless of the MR gene mutation status.